Immix Biopharma, Inc. (IMMX) stock
IMMXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$7.84−0.23 (-2.85%)
Close on Nov 13, 2026Market cap $560.87MP/E –Yield –
Immix Biopharma cash
Cash and short-term investments held at the end of each period.
Immix Biopharma's cash was $336.30M at Sep 30, 2026. For fiscal 2025 it was $100.40M, up 467.8% from the year before. The highest annual figure on record is $100.40M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $100.40M | +467.8% |
| FY2024 | Dec 31, 2024 | $17.68M | +1.0% |
| FY2023 | Dec 31, 2023 | $17.51M | +30.3% |
| FY2022 | Dec 31, 2022 | $13.44M | -23.8% |
| FY2021 | Dec 31, 2021 | $17.64M | +4411.7% |
| FY2020 | Dec 31, 2020 | $391.09K | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $336.30M | +2008.8% |
| Q2 FY2026 | Jun 30, 2026 | $232.10M | +1894.3% |
| Q1 FY2026 | Mar 31, 2026 | $90.60M | +469.1% |
| Q4 FY2025 | Dec 31, 2025 | $100.40M | +467.8% |
| Q3 FY2025 | Sep 30, 2025 | $15.95M | -19.0% |
| Q2 FY2025 | Jun 30, 2025 | $11.64M | -51.5% |
| Q1 FY2025 | Mar 31, 2025 | $15.92M | -45.7% |
| Q4 FY2024 | Dec 31, 2024 | $17.68M | +1.0% |
| Q3 FY2024 | Sep 30, 2024 | $19.69M | +0.6% |
| Q2 FY2024 | Jun 30, 2024 | $23.98M | +89.5% |
| Q1 FY2024 | Mar 31, 2024 | $29.32M | +155.8% |
| Q4 FY2023 | Dec 31, 2023 | $17.51M | +30.3% |
| Q3 FY2023 | Sep 30, 2023 | $19.58M | +15.8% |
| Q2 FY2023 | Jun 30, 2023 | $12.65M | -31.2% |
| Q1 FY2023 | Mar 31, 2023 | $11.46M | -39.9% |
| Q4 FY2022 | Dec 31, 2022 | $13.44M | -23.8% |
| Q3 FY2022 | Sep 30, 2022 | $16.92M | +4225.5% |
| Q2 FY2022 | Jun 30, 2022 | $18.40M | – |
| Q1 FY2022 | Mar 31, 2022 | $19.06M | – |
| Q4 FY2021 | Dec 31, 2021 | $17.64M | – |
| Q4 FY2020 | Dec 31, 2020 | $391.09K | – |
See a number that looks wrong?